116 related articles for article (PubMed ID: 24879095)
1. Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia.
Tse E; Leung RY; Kwong YL
Ann Hematol; 2015 Jan; 94(1):165-7. PubMed ID: 24879095
[No Abstract] [Full Text] [Related]
2. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
[No Abstract] [Full Text] [Related]
3. Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia.
Henn A; Mellon G; Benoît H; Roos-Weil D; Jauréguiberry S; Mordant P; Fekkar A; Caumes E
Scand J Infect Dis; 2014 Mar; 46(3):231-4. PubMed ID: 24450842
[TBL] [Abstract][Full Text] [Related]
4. Obinutuzumab use complicated by progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukemia: a case report.
Turine G; London F
Acta Neurol Belg; 2021 Jun; 121(3):781-783. PubMed ID: 33063195
[No Abstract] [Full Text] [Related]
5. Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C; Salles G
Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
[TBL] [Abstract][Full Text] [Related]
6. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia.
Gay ND; Kozin E; Okada C; Danilov AV; Spurgeon S
Leuk Lymphoma; 2018 Sep; 59(9):2258-2260. PubMed ID: 29249186
[No Abstract] [Full Text] [Related]
8. The use of obinutuzumab in chronic lymphocytic leukemia.
Wierda W
Clin Adv Hematol Oncol; 2014 Jun; 12(6):395-7. PubMed ID: 25003571
[No Abstract] [Full Text] [Related]
9. Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy.
Traynor K
Am J Health Syst Pharm; 2013 Dec; 70(24):2162. PubMed ID: 24296835
[No Abstract] [Full Text] [Related]
10. Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab.
Niscola P; Ragusa D; Scaramucci L; Giovannini M; Piccioni D; Tendas A; Perrotti A; de Fabritiis P; Del Poeta G
Ann Hematol; 2014 May; 93(5):863-5. PubMed ID: 23949377
[No Abstract] [Full Text] [Related]
11. Obinutuzumab in chronic lymphocytic leukemia.
Dupuis J
Future Oncol; 2015 Sep; 11(18):2503-13. PubMed ID: 26285615
[TBL] [Abstract][Full Text] [Related]
12. Prevention and management of obinutuzumab-associated toxicities: Australian experience.
Snowden A; Hayden I; Dixon J; Gregory G
Int J Nurs Pract; 2015 Dec; 21 Suppl 3():15-27. PubMed ID: 26681665
[TBL] [Abstract][Full Text] [Related]
13. Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia.
Korman AM; Hastings JG; Byrd JC; Kaffenberger BH
JAMA Dermatol; 2017 Jan; 153(1):108-110. PubMed ID: 27892987
[No Abstract] [Full Text] [Related]
14. Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia.
Small S
Clin Adv Hematol Oncol; 2013 Dec; 11(12):809-10. PubMed ID: 25016628
[No Abstract] [Full Text] [Related]
15. Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient.
Benetatos L; Hatzimichael E; Vassou A; Bourantas KL
Leuk Res; 2007 Jan; 31(1):119-20. PubMed ID: 16620969
[No Abstract] [Full Text] [Related]
16. Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes).
Braester A; Akria L; Suriu C; Sonkin V
Acta Haematol; 2013; 129(3):185-6. PubMed ID: 23257842
[No Abstract] [Full Text] [Related]
17. Prostatic and renal aspergillosis due to Aspergillus fumigatus in a patient receiving alemtuzumab for chronic lymphocytic leukaemia.
Roux C; Thyss A; Gari-Toussaint M
J Mycol Med; 2013 Dec; 23(4):270-3. PubMed ID: 24210582
[TBL] [Abstract][Full Text] [Related]
18. Aspergillus fumigatus osteomyelitis in a patient receiving alemtuzumab for B-cell chronic lymphocytic leukaemia.
Karia S; Jeyapalan K; Kennedy B
Br J Haematol; 2011 Apr; 153(2):147. PubMed ID: 21332707
[No Abstract] [Full Text] [Related]
19. Pact with the devil: alemtuzumab therapy, immune suppression and infectious complications in chronic lymphocytic leukemia.
Antohe I; Dascalescu A; Burcoveanu C; Ghiorghiu D; Dascalu A; Danaila C
Rev Med Chir Soc Med Nat Iasi; 2014; 118(1):92-5. PubMed ID: 24741782
[TBL] [Abstract][Full Text] [Related]
20. Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies.
Kittai AS; Best S; Thurlow B; Lam V; Hashiguchi T; Goodyear S; Persky DO; Okada C; Park B; Spurgeon SE; Danilov AV
Haematologica; 2021 Jul; 106(7):2022-2025. PubMed ID: 33504141
[No Abstract] [Full Text] [Related]
[Next] [New Search]
